Enterprise Value

162.6M

Cash

83.04M

Avg Qtr Burn

-7.714M

Short % of Float

5.37%

Insider Ownership

2.49%

Institutional Own.

61.36%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Reproxalap Details
Dry eye syndrome

NDA

Resubmission

ADX-2191 (methotrexate injection (DHFR inhibitor)) Details
Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma, Retinitis Pigmentosa

NDA

FDA meeting

Reproxalap (ADX-102) Details
Rare genetic disease, Rare diseases, Allergic conjunctivitis

Phase 3

Update

ADX-629 Details
Alcoholic hepatitis, Liver disease

Phase 2

Data readout

ADX-629 Details
Chronic cough

Phase 2

Update

ADX-629 Details
Sjögren-Larsson Syndrome

Phase 2

Update

ADX-629 Details
Idiopathic Nephrotic Syndrome

Phase 2a

Data readout

ADX-629 Details
Atopic dermatitis

Phase 2a

Update

ADX-246 Details
Atopic dermatitis, Skin disease/disorder

Phase 1/2

Data readout